Emergence Therapeutics
Latest round
- Series A
Last raised
- Dec 2021
Total raised
- $98M
Investors
- 13
About Emergence Therapeutics
Founded in 2019 and based in Duisburg, Germany, Emergence Therapeutics AG is a developer of novel antibody-drug conjugate immuno-therapeutics intended to treat cancer. The company uses ATAC technology to target Nectin-4 providing doctors and healthcare organizations with an effective drug as a therapy tool to treat cancer.
Who invested in Emergence Therapeutics
13 investors across 2 rounds
See all investors in Emergence Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Emergence Therapeutics
Who invested in Emergence Therapeutics?
Emergence Therapeutics has 13 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Emergence Therapeutics raised?
Emergence Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Emergence Therapeutics last raise money?
Emergence Therapeutics's most recent round on record is a Series A, in Dec 2021.
What does Emergence Therapeutics do?
Founded in 2019 and based in Duisburg, Germany, Emergence Therapeutics AG is a developer of novel antibody-drug conjugate immuno-therapeutics intended to treat cancer.
Where is Emergence Therapeutics headquartered?
Emergence Therapeutics is headquartered in Duisburg, Germany.
Which VCs invest in companies like Emergence Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Emergence Therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Emergence Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.